Jul 15, 2025 08:06AM IMUNON receives Nasdaq extension to complete compliance plan

Jun 20, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Imunon (IMNN)

Jun 18, 2025 08:05AM Imunon (IMNN) Presents Positive Phase 2 Translational Data of IMNN-001

Jun 17, 2025 08:05AM Imunon (IMNN) Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development

Jun 3, 2025 08:07AM Imunon (IMNN) Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

May 15, 2025 08:06AM Imunon (IMNN) Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Trial in COVID-19

May 8, 2025 08:05AM Imunon (IMNN) Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025 08:05AM Imunon (IMNN) Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy

Mar 24, 2025 08:05AM Imunon (IMNN) Finalizes Phase 3 Study Design with FDA for IMNN-001

Feb 28, 2025 08:09AM Imunon (IMNN) PT Raised to $14 at H.C. Wainwright

Nov 26, 2024 07:06AM H.C. Wainwright Reiterates Buy Rating on Imunon (IMNN)

Nov 7, 2024 08:09AM Celsion Corporation (IMNN) Tops Q3 EPS by 5c

Sep 23, 2024 07:02AM EF Hutton Starts Imunon (IMNN) at Buy

Aug 14, 2024 08:06AM Celsion Corporation (IMNN) Reports Q2 Loss of $0.51

Jul 31, 2024 08:35AM Imunon (IMNN) Announces $10 Million Registered Direct Offering

Jun 24, 2024 08:35AM IMUNON (IMNN) Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer